A randomized phase II/III study of 'novel therapeutics' versus azacitidine in newly diagnosed patients with acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML), age 60 or older: a report of the comparison of azacitidine and nivolumab to azacitidine: SWOG S1612
一项针对60岁及以上新诊断急性髓系白血病(AML)、高危骨髓增生异常综合征(MDS)或慢性粒单核细胞白血病(CMML)患者的随机II/III期研究,比较了“新型疗法”与阿扎胞苷的疗效:阿扎胞苷联合纳武利尤单抗与阿扎胞苷的比较报告:SWOG S1612
期刊:Leukemia & Lymphoma
影响因子:2.2
doi:10.1080/10428194.2022.2148212
Assouline, Sarit; Michaelis, Laura C; Othus, Megan; Hay, Annette E; Walter, Roland B; Jacoby, Meagan A; Schroeder, Mark A; Uy, Geoffrey L; Law, Lisa Y; Cheema, Faisal; Sweet, Kendra L; Asch, Adam S; Liu, Jijun Jane; Moseley, Anna B; Maher, Tracy; Kingsbury, Laura L; Fang, Min; Radich, Jerald; Little, Richard F; Erba, Harry P